| Cat. No. |
Size |
Price |
Figures |
|---|
RP10222-5 mg
| 5 mg | $ 118.75 | MSDS: 20080727034235 (PDF)
References:
- Massari D, et al. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. J. Neuroimmunol. Dec 2002; 133(1-2): 211-216.
- Muhvic D, et al. Induction of experimental allergic encephalomyelitis in a low-susceptible Albino Oxford rat strain by somatostatin analogue SMS 201-995. Neuroimmunomodulation. 2005; 12(1): 20-28.
- Massari D, et al. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. Anticancer Drugs. Oct 2005; 16(9): 989-996.
|
|---|
| Full Name | |
| Alias |
Somatostatin analogue |
Sequence
(one-letter code) |
FCFWKTCT-OL |
Sequence
(three-letter code) | {d-PHE}{CYS}{PHE}{d-TRP}{LYS}{THR}{CYS}{THR}-ol |
|---|
| C-Terminal | OL |
|---|
| Chemical Bridge | Cys2-Cys7 |
|---|
| Description | SMS 201-995 belongs to somatostatin analog that is three times more potent than the native hormone in inhibiting the secretion of growth hormone. SMS 201-995 can lower plasma concentrations of growth hormone and somatomedin-C in patients with pituitary acromegaly. Somatostatin analogues have been suggested as possible therapy for human pancreatic cancer. |
|---|
| Solubility | The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents. |
|---|
| Formula | C49H66N10O10S2 |
|---|
| M.W. | 1019.24 |
|---|
| Cas | 79517-01-4 |
|---|
| Purity | > 95% |
|---|
| Storage | Before use, store the peptide in the DRY form at 0°C - 5°C. For best and most repeatable results, rehydrate the peptide immediately before use. Do not re-freeze any unused portions. |
